A detailed history of Charles Schwab Investment Management Inc transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 739,530 shares of CRBU stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
739,530
Previous 621,205 19.05%
Holding current value
$1.45 Million
Previous $1.02 Million 41.65%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.56 - $2.73 $184,587 - $323,027
118,325 Added 19.05%
739,530 $1.44 Million
Q2 2024

Aug 12, 2024

SELL
$1.62 - $5.05 $329,592 - $1.03 Million
-203,452 Reduced 24.67%
621,205 $1.02 Million
Q1 2024

May 08, 2024

BUY
$4.82 - $8.26 $81,448 - $139,577
16,898 Added 2.09%
824,657 $4.24 Million
Q4 2023

Feb 06, 2024

BUY
$3.58 - $6.25 $772,957 - $1.35 Million
215,910 Added 36.48%
807,759 $4.63 Million
Q3 2023

Nov 08, 2023

BUY
$4.08 - $8.14 $731,233 - $1.46 Million
179,224 Added 43.44%
591,849 $2.83 Million
Q2 2023

Aug 09, 2023

BUY
$4.04 - $5.47 $8,791 - $11,902
2,176 Added 0.53%
412,625 $1.75 Million
Q1 2023

May 11, 2023

BUY
$4.3 - $7.78 $23,852 - $43,155
5,547 Added 1.37%
410,449 $2.18 Million
Q4 2022

Feb 13, 2023

BUY
$5.57 - $11.01 $34,483 - $68,162
6,191 Added 1.55%
404,902 $2.54 Million
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $1.02 Million - $2.45 Million
191,492 Added 92.41%
398,711 $4.21 Million
Q2 2022

Aug 15, 2022

SELL
$5.1 - $9.74 $37,362 - $71,355
-7,326 Reduced 3.41%
207,219 $1.13 Million
Q1 2022

May 13, 2022

BUY
$8.42 - $15.32 $606,484 - $1.1 Million
72,029 Added 50.54%
214,545 $1.97 Million
Q4 2021

Feb 11, 2022

BUY
$14.59 - $23.26 $134,797 - $214,899
9,239 Added 6.93%
142,516 $2.15 Million
Q3 2021

Nov 16, 2021

BUY
$15.75 - $30.29 $2.1 Million - $4.04 Million
133,277 New
133,277 $3.18 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $119M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.